Rutin metabolites: Novel inhibitors of nonoxidative advanced glycation end products

Free Radical Biology and Medicine

Volumn 48, Issue 5, 2010, Pages 656-663

  Pashikanti, Srinath ^a   de Alba, David R ^a   Boissonneault, Gilbert A ^b   Cervantes Laurean, Daniel ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Diet; Flavonoids; Free radicals; Glycation; Rutin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYTOLUENE; ADENOSINE DIPHOSPHATE RIBOSE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; DICARBOXYLIC AMINO ACID; GLYOXAL; HISTONE H1; HOMOVANILLIC ACID; METHYLGLYOXAL; N CARBOXYMETHYLLYSINE; PHENOL DERIVATIVE; RUTOSIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; IN VITRO STUDY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

ADENOSINE DIPHOSPHATE RIBOSE; AGING; CATECHOLAMINES; CATECHOLS; DIABETES COMPLICATIONS; DIET THERAPY; FLAVONOIDS; FRUIT; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; HISTONES; HUMANS; RUTIN; VEGETABLES;

EID: 75149160421     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.11.019     Document Type: Article

References (52)

1. Agalou S., Ahmed N., Dawnay A., and Thornalley PJ. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem. Soc. Trans. 31 (2003) 1394-1396
2. Akhand A.A., Hossain K., Kato M., Miyata T., Du J., Suzuki H., Kurokawa K., and Nakashima I. Glyoxal and methylglyoxal induce aggregation and inactivation of ERK in human endothelial cells. Free Radic. Biol. Med. 31 (2001) 1228-1235
3. Lapolla A., Flamini R., Tonus T., Fedele D., Senesi A., Reitano R., Marotta E., Pace G., Seraglia R., and Traldi P. An effective derivatization method for quantitative determination of glyoxal and methylglyoxal in plasma samples by gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 17 (2003) 876-878
4. Odani H., Shinzato T., Matsumoto Y., Usami J., and Maeda K. Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 256 (1999) 89-93
5. Thornalley P.J., Hooper N.I., Jennings P.E., Florkowski C.M., Jones A.F., Lunec J., and Barnett AH. The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res. Clin. Pract. 7 (1989) 115-120
6. Lyons T.J., Bailie K.E., Dyer D.G., Dunn J.A., and Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J. Clin. Invest. 87 (1991) 1910-1915
7. Mizutari K., Ono T., Ikeda K., Kayashima K., and Horiuchi S. Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J. Invest. Dermatol. 108 (1997) 797-802
8. Baynes J.W., and Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28 (2000) 1708-1716
9. Anderson M.M., Hazen S.L., Hsu F.F., and Heinecke J.W. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein: a mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 99 (1997) 424-432
10. Glomb M.A., and Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 270 (1995) 10017-10026
11. Anderson M.M., Requena J.R., Crowley J.R., Thorpe S.R., and Heinecke J.W. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 104 (1999) 103-113
12. Dunn J.A., McCance D.R., Thorpe S.R., Lyons T.J., and Baynes J.W. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30 (1991) 1205-1210
13. Monnier V.M., Sell D.R., Nagaraj R.H., Miyata S., Grandhee S., Odetti P., and Ibrahim S.A. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41 Suppl. 2 (1992) 36-41
14. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
15. Baynes J.W., Watkins N.G., Fisher C.I., Hull C.J., Patrick J.S., Ahmed M.U., Dunn J.A., and Thorpe S.R. The Amadori product on protein: structure and reactions. Prog. Clin. Biol. Res. 304 (1989) 43-67
16. Edelstein D., and Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35 (1992) 96-97
17. Ou P., and Wolff S.P. Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem. Pharmacol. 46 (1993) 1139-1144
18. Freedman B.I., Wuerth J.P., Cartwright K., Bain R.P., Dippe S., Hershon K., Mooradian A.D., and Spinowitz BS. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials 20 (1999) 493-510
19. Okuda Y., Sakoda S., Fujimura H., and Yanagihara T. Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. J. Neuroimmunol. 81 (1998) 201-210
20. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., and Baynes J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43 (1994) 676-683
21. Sell D.R., Biemel K.M., Reihl O., Lederer M.O., Strauch C.M., and Monnier V.M. Glucosepane is a major protein cross-link of the senescent human extracellular matrix: relationship with diabetes. J. Biol. Chem. 280 (2005) 12310-12315
22. Jacobson E.L., Cervantes-Laurean D., and Jacobson MK. ADP-ribose in glycation and glycoxidation reactions. Adv. Exp. Med. Biol. 419 (1997) 371-379
23. Cervantes-Laurean D., Jacobson E.L., and Jacobson MK. Glycation and glycoxidation of histones by ADP-ribose. J. Biol. Chem. 271 (1996) 10461-10469
24. Jacobson E.L., Cervantes-Laurean D., and Jacobson MK. Glycation of proteins by ADP-ribose. Mol. Cell. Biochem. 138 (1994) 207-212
25. Cervantes-Laurean D., Minter D.E., Jacobson E.L., and Jacobson M.K. Protein glycation by ADP-ribose: studies of model conjugates. Biochemistry 32 (1993) 1528-15234
26. Cardenas-Corona M.E., Jacobson E.L., and Jacobson MK. Endogenous polymers of ADP-ribose are associated with the nuclear matrix. J. Biol. Chem. 262 (1987) 14863-14866
27. Wondrak G.T., Cervantes-Laurean D., Jacobson E.L., and Jacobson MK. Histone carbonylation in vivo and in vitro. Biochem. J. 351 Pt 3 (2000) 769-777
28. Winter J., Moore L.H., Dowell Jr. V.R., and Bokkenheuser VD. C-ring cleavage of flavonoids by human intestinal bacteria. Appl. Environ. Microbiol. 55 (1989) 1203-1208
29. Odetti P.R., Borgoglio A., De Pascale A., Rolandi R., and Adezati L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39 (1990) 796-801
30. Braune A., Gutschow M., Engst W., and Blaut M. Degradation of quercetin and luteolin by Eubacterium ramulus. Appl. Environ. Microbiol. 67 (2001) 5558-55567
31. Griffiths L.A., and Barrow A. Metabolism of flavonoid compounds in germ-free rats. Biochem. J. 130 (1972) 1161-1162
32. Schneider H., Simmering R., Hartmann L., Pforte H., and Blaut M. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J. Appl. Microbiol. 89 (2000) 1027-1037
33. Baba S., Furuta T., Fujioka M., and Goromaru T. Studies on drug metabolism by use of isotopes. XXVII. Urinary metabolites of rutin in rats and the role of intestinal microflora in the metabolism of rutin. J. Pharm. Sci. 72 (1983) 1155-1158
34. Baba S., Furuta T., Horie M., and Nakagawa H. Studies on drug metabolism by use of isotopes. XXVI. Determination of urinary metabolites of rutin in humans. J. Pharm. Sci. 70 (1981) 780-782
35. Erlund I., Kosonen T., Alfthan G., Maenpaa J., Perttunen K., Kenraali J., Parantainen J., and Aro A. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur. J. Clin. Pharmacol. 56 (2000) 545-553
36. Sawai Y., Kohsaka K., Nishiyama Y., and Ando K. Serum concentrations of rutoside metabolites after oral administration of a rutoside formulation to humans. Arzneimittelforschung 37 (1987) 729-732
37. Olthof M.R., Hollman P.C., Buijsman M.N., van Amelsvoort J.M., and Katan MB. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J. Nutr. 133 (2003) 1806-1814
38. Cervantes-Laurean D., Roberts M.J., Jacobson E.L., and Jacobson MK. Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. Free Radic. Biol. Med. 38 (2005) 786-795
39. Cervantes-Laurean D., Schramm D.D., Jacobson E.L., Halaweish I., Bruckner G.G., and Boissonneault GA. Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J. Nutr. Biochem. 17 (2006) 531-540
40. Johns E.W. The isolation and purification of histones. Methods Cell Biol. 16 (1977) 183-203
41. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46 (1995) 223-234
42. Manske CL. Coronary artery disease in diabetic patients with nephropathy. Am. J. Hypertens. 6 (1993) 367S-374S
43. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1 (1995) 693-699
44. Gilbert R.E., Connelly K., Kelly D.J., Pollock C.A., and Krum H. Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. Clin. J. Am. Soc. Nephrol. 1 (2006) 193-208
45. Nagasawa T., Tabata N., Ito Y., Aiba Y., Nishizawa N., and Kitts DD. Dietary G-rutin suppresses glycation in tissue proteins of streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 252 (2003) 141-147
46. Nagasawa T., Tabata N., Ito Y., Nishizawa N., Aiba Y., and Kitts DD. Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative. Mol. Cell. Biochem. 249 (2003) 3-10
47. Brownlee M. The pathological implications of protein glycation. Clin. Invest. Med. 18 (1995) 275-281
48. Wondrak G.T., Cervantes-Laurean D., Roberts M.J., Qasem J.G., Kim M., Jacobson E.L., and Jacobson MK. Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress. Biochem. Pharmacol. 63 (2002) 361-373
49. Litchfield J.E., Thorpe S.R., and Baynes J.W. Oxygen is not required for the browning and crosslinking of protein by pentoses: relevance to Maillard reactions in vivo. Int. J. Biochem. Cell Biol. 31 (1999) 1297-1305
50. McLellan A.C., Thornalley P.J., Benn J., and Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. (London) 87 (1994) 21-29
51. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet. 24 (1976) 117-191
52. Conquer J.A., Maiani G., Azzini E., Raguzzini A., and Holub BJ. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 128 (1998) 593-597